Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Dariush Norouzian
Total Records ( 3 ) for Dariush Norouzian
  Ali Sharifat Salmani , Seyed Davar Siadat , Mohammad Reza Fallahian , Hojat Ahmadi , Dariush Norouzian , Parichehr Yaghmai and Mohammad Reza Aghasadeghi
  Problem statement: Brucellosis is a globally found infectious disease and there is no licensed vaccine against human brucellosis. The present study carried-out to evaluate the potency of our modified extracted lipopolysaccharide (LPS) of B. abortus to elicit specific anti-Brucella antibodies in animal model (Rabbit) as a part of a candidate vaccine for brucellosis. Lipopolysaccharide is one of the main virulence factors and the most immunogenic structure of smooth strains of Brucella. Approach: Lipopolysaccharide of B. abortus S99 (S-LPS) initially extracted through an optimized method as described previously. After biochemical and pyrogenicity evaluations of the extracted S-LPS humoral immune response against the extracted LPS analyzed in animal model through serological assays such as Rose Bengal assay, Rapid agglutination (Rapid Wright) test and Standard agglutination test (SAT or Wright test) to demonstrate the specific elicited antibodies against the injected LPS. In addition, the interaction of LPS and anti-LPS antibodies was demonstrated by Agarose Gel Immunodiffusion (AGID) assay. Results: Higher doses of B. abortus S99 LPS caused less or equal body temperature increase in comparison to E. coli LPS doses. Sera of immunized animals had been reported positive by RBT because of B. abortus LPS immunogenicity which we extracted through our optimized method. The highest titer of anti-Brucella antibodies detected two weeks after the third immunization (assayed by rapid slide agglutination and standard agglutination tests). Anti-Brucella antibodies of immunized animals reacted more specifically with the LPS of B. abortus in comparison with E. coli LPS and precipitation lines between B. abortus LPS and immune sera appeared after 30 min while detected after three hours for E. coli LPS. Conclusions/Recommendations: The properties of B. abortus S99 LPS concluded from the present study results, suggest the possible use of this component as a carrier or a part of a sub-unit or conjugated vaccine for human brucellosis.
  Dariush Norouzian , Azim Akbarzadeh , Saeed Mirdamadi , Shohreh Khetami and Ali Farhanghi
  Tyrosinase of edible mushroom was immobilized on activated agar particles, blocks and egg shell powder coated with polyethyleneimine (PEI) so as to study their efficiency in the transformation of L-tyrosine to L-dopa. The reaction rate for each form (PEI coated egg shell powder, activated agar blocks and activated agar particles) of the immobilized tyrosinase was calculated to be 0.0021, 0.018 and 0.0032 min, respectively. Desorption of tyrosinase from each support was found to be negligible. The production of L-dopa was 25, 73 and 42 mg L-1 for tyrosinase immobilized onto egg shell powder coated with PEI, activated agar particles and blocks, respectively.
  Nima Rezaei , Asghar Aghamohammadi , Seyed Davar Siadat , Mostafa Moin , Zahra Pourpak , Mehdi Nejati , Hojat Ahmadi , Samineh Kamali , Dariush Norouzian , Bahman Tabaraei and Robert C. Read
  Common variable immunodeficiency (CVID) is a heterogeneous group of disorders characterized by hypogammaglobulinemia and increased susceptibility to recurrent pyogenic infections. This study was performed to subclassify CVID on the basis of the bactericidal antibody responses of patients to polysaccharide meningococcal vaccine. Twenty-five patients with CVID (18 male and 7 female) and 25 healthy volunteers received meningococcal polysaccharide vaccine A + C. Serum bactericidal antibody (SBA) titers were measured at baseline and after 3 weeks. Response was correlated with clinical and immunological manifestations of CVID. Twenty-four (96%) of the 25 normal controls had a protective SBA titer of ≥8 postvaccination, whereas only 16 (64%) of the 25 CVID patients had a protective titer (P value = 0.013). Among the patients with CVID who were nonresponders, there were significantly increased rates of bronchiectasis (P = 0.008), splenomegaly (P = 0.016), and autoimmunity (P = 0.034) in comparison with patients who had protective SBA titers. A reversed CD4/CD8 ratio was more common in the nonresponder group of patients (P = 0.053). We conclude that individuals with CVID who cannot produce protective postvaccination titers after receiving meningococcal polysaccharide vaccine are more likely to exhibit bronchiectasis, splenomegaly, and autoimmune diseases. Vaccination response may define subgroups of patients with CVID, enabling more effective monitoring and therapeutic strategies.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility